全文获取类型
收费全文 | 7115篇 |
免费 | 365篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 132篇 |
妇产科学 | 87篇 |
基础医学 | 902篇 |
口腔科学 | 149篇 |
临床医学 | 420篇 |
内科学 | 2119篇 |
皮肤病学 | 131篇 |
神经病学 | 512篇 |
特种医学 | 193篇 |
外科学 | 988篇 |
综合类 | 46篇 |
预防医学 | 233篇 |
眼科学 | 106篇 |
药学 | 528篇 |
中国医学 | 8篇 |
肿瘤学 | 943篇 |
出版年
2023年 | 30篇 |
2022年 | 36篇 |
2021年 | 131篇 |
2020年 | 104篇 |
2019年 | 126篇 |
2018年 | 199篇 |
2017年 | 149篇 |
2016年 | 151篇 |
2015年 | 179篇 |
2014年 | 249篇 |
2013年 | 314篇 |
2012年 | 487篇 |
2011年 | 563篇 |
2010年 | 307篇 |
2009年 | 244篇 |
2008年 | 444篇 |
2007年 | 515篇 |
2006年 | 478篇 |
2005年 | 444篇 |
2004年 | 463篇 |
2003年 | 434篇 |
2002年 | 481篇 |
2001年 | 73篇 |
2000年 | 51篇 |
1999年 | 80篇 |
1998年 | 92篇 |
1997年 | 67篇 |
1996年 | 77篇 |
1995年 | 82篇 |
1994年 | 67篇 |
1993年 | 61篇 |
1992年 | 52篇 |
1991年 | 34篇 |
1990年 | 27篇 |
1989年 | 36篇 |
1988年 | 28篇 |
1987年 | 27篇 |
1986年 | 20篇 |
1985年 | 19篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 13篇 |
1981年 | 15篇 |
1980年 | 17篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1975年 | 7篇 |
1965年 | 4篇 |
排序方式: 共有7558条查询结果,搜索用时 31 毫秒
1.
2.
Naoki Takegawa Junji Tsurutani Hisato Kawakami Kimio Yonesaka Ryoji Kato Koji Haratani Hidetoshi Hayashi Masayuki Takeda Yoshikane Nonagase Osamu Maenishi Kazuhiko Nakagawa 《International journal of cancer. Journal international du cancer》2019,145(12):3414-3424
Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven effective against tumors positive for HER2 amplification, but there is an unmet clinical need for the treatment of tumors that express HER2 protein in the absence of HER2 amplification. [fam-] trastuzumab deruxtecan (DS-8201a) is a novel antibody–drug conjugate composed of the anti-HER2 antibody and the topoisomerase I inhibitor, an exatecan derivative. It has shown efficacy against tumors that express HER2 and is currently under evaluation in clinical trials. We here show that the antitumor activity of [fam-] trastuzumab deruxtecan is dependent on the expression level of HER2 protein in colorectal cancer (CRC) cell lines negative for HER2 amplification. We established isogenic CRC cell lines that express various levels of HER2 protein in the absence of HER2 amplification, and we found that cells that express HER2 at a high level were sensitive to [fam-] trastuzumab deruxtecan but not to conventional HER2-targeted therapies. Furthermore, [fam-] trastuzumab deruxtecan manifested a bystander killing effect both in vitro and in vivo, with cells essentially negative for HER2 expression also being killed in the presence of HER2-expressing cells, an effect that has the potential to overcome heterogeneity of HER2 expression in CRC tumors. Our results thus suggest that [fam-] trastuzumab deruxtecan warrants further study as a potential treatment for CRC tumors that express HER2 protein in the absence of HER2 amplification. 相似文献
3.
4.
Norito Katoh Hidehisa Saeki Yoko Kataoka Takafumi Etoh Satoshi Teramukai Hiroki Takagi Yuki Tajima Marius Ardeleanu Elena Rizova Kazuhiko Arima 《The Journal of dermatology》2019,46(4):290-300
Moderate to severe atopic dermatitis (AD) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long‐term disease control in the Japanese population. ADDRESS‐J is a non‐interventional, observational registry of adult Japanese patients with moderate to severe AD. Herein, we report baseline data from the ADDRESS‐J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment (IGA) scores (range, 0–4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient‐reported outcomes and current AD treatments. The registry patients’ median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0–72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0–10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD. This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments. 相似文献
5.
6.
7.
8.
Kazuhiko Yoshida Masumi Tsuda Ryuji Matsumoto Shingo Semba Lei Wang Hirokazu Sugino Mishie Tanino Tsunenori Kondo Kazunari Tanabe Shinya Tanaka 《Cancer science》2019,110(7):2119-2132
Locally advanced and metastatic invasive bladder cancer (BC) has a poor prognosis, and no advanced therapies beyond cisplatin‐based combination chemotherapy have been developed. Therefore, it is an urgent issue to elucidate the underlying mechanisms of tumor progression and metastasis of invasive BC for the development of new therapeutic strategies. Here, we clarified a novel role of exosomes containing ErbB2 and CRK in a formation of premetastatic niches and subsequent metastases. CRK adaptors were overexpressed in invasive UM‐UC‐3 BC cells. In an orthotopic xenograft model, metastases to lung, liver, and bone of UM‐UC‐3 cells were completely abolished by CRK elimination. Mass spectrometry analysis identified that ErbB2 was contained in UM‐UC‐3‐derived exosomes in a CRK‐dependent manner; the exosomes significantly increased proliferation and invasion properties of low‐grade 5637 BC cells and HUVECs through FAK and PI3K/AKT signaling pathways. In athymic mice educated with UM‐UC‐3‐derived exosomes, i.v. implanted UM‐UC‐3 cells were trapped with surrounding PKH67‐labeled exosomes in lung and led to development of lung metastasis with disordered vascular proliferation. In contrast, exosomes derived from CRK‐depleted BC cells failed to induce these malignant features. Taken together, we showed that CRK adaptors elevated the expression of ErbB2/3 in BC cells, and these tyrosine kinase/adaptor units were transferred from host BC cells to metastatic recipient cells by exosomes, leading to vascular leakiness and proliferation and contributing to the formation of distant metastasis. Thus, CRK intervention with ErbB2/3 blockade might be a potent therapeutic strategy for patients with ErbB2 overexpressing advanced and metastatic BC. 相似文献
9.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
10.